BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics
06 sept. 2023 06h00 HE
|
BiondVax Pharmaceuticals Ltd.
JERUSALEM, Sept. 06, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company, is pleased to announce today a change of its corporate name to...
BiondVax Reports Second Quarter Financial Results and Provides Business Update
11 août 2023 09h00 HE
|
BiondVax Pharmaceuticals Ltd.
JERUSALEM, Aug. 11, 2023 (GLOBE NEWSWIRE) -- via IBN - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative...
Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules
01 août 2023 16h01 HE
|
BiondVax Pharmaceuticals Ltd.
JERUSALEM, Aug. 01, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative...
BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis
05 juin 2023 07h00 HE
|
BiondVax Pharmaceuticals Ltd.
Broad-based collaboration with Max Planck and University Medical Center Gottingen yields attractive anti-IL-17 VHH antibodies (NanoAbs); includes exclusive worldwide license for all potential...
BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update
17 avr. 2023 16h25 HE
|
BiondVax Pharmaceuticals Ltd.
JERUSALEM, April 17, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing...
BiondVax to Present at BIO-Europe Spring
16 mars 2023 13h10 HE
|
BiondVax Pharmaceuticals Ltd.
JERUSALEM, March 16, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing...
BiondVax Presenting at BIO CEO & Investor Conference
02 févr. 2023 14h15 HE
|
BiondVax Pharmaceuticals Ltd.
JERUSALEM, Feb. 02, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing...
BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study
23 janv. 2023 06h25 HE
|
BiondVax Pharmaceuticals Ltd.
COVID-19 illness was virtually prevented in hamsters administered BiondVax’s inhaled NanoAb and infected three hours later with SARS-CoV-2 Data further strengthens value proposition of BiondVax’s...
BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study
06 janv. 2023 07h15 HE
|
BiondVax Pharmaceuticals Ltd.
Hamsters infected with SARS-COV-2 and then treated with BiondVax’s inhaled anti-COVID-19 nanosized antibodies (NanoAbs) had over 30-times lower lung viral titer on average compared to those treated...
BiondVax to Present at Biotech Showcase 2023
05 janv. 2023 07h00 HE
|
BiondVax Pharmaceuticals Ltd.
JERUSALEM, Jan. 05, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing...